Biotech M&A returns as Vertex, Innoviva make buys - Boston Business Journal

With the ViaCyte deal, Vertex will further expand its cell and gene therapy business, which is already central to its growth strategy.
https://www.google.com/url?rct=j&sa=t&url=https://www.bizjournals.com/boston/news/2022/07/12/biotech-m-a-returns-as-vertex-innoviva-make-buys.html&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AOvVaw0ahQ17YcMlkZQwTh0GGcKW